US Stock MarketDetailed Quotes
CNTA Centessa Pharmaceuticals
- 8.930
- -0.530-5.60%
Close Apr 25 16:00 ET
- 8.930
- 0.0000.00%
Post 16:00 ET
895.73MMarket Cap-5687P/E (TTM)
9.387High8.900Low286.60KVolume9.260Open9.460Pre Close2.61MTurnover0.65%Turnover RatioLossP/E (Static)100.31MShares12.45052wk High3.79P/B391.93MFloat Cap3.96052wk Low--Dividend TTM43.89MShs Float26.900Historical High--Div YieldTTM5.14%Amplitude2.885Historical Low9.117Avg Price1Lot Size
Centessa Pharmaceuticals Stock Forum
Sign in to post a comment
Update
$Centessa Pharmaceuticals(CNTA.US$ Press Release: Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
Dow Jones· 15 mins ago
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for p...
Dow Jones· 15 mins ago
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for p...
10
Update
$Centessa Pharmaceuticals(CNTA.US$ The FDA Has Cleared Centessa Pharmaceuticals' Investigational New Drug Application To Initiate A Phase 1 First-in-human, Clinical Trial Of ORX750 For Narcolepsy
4
Gear up for AACR24!
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
Update
$Centessa Pharmaceuticals(CNTA.US$ BOSTON and LONDON, Dec. 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia. The data were shared in a poster presentation at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 10, 2023. SerpinPC is an investigational subcutaneously...
2
ColumnsToday's Pre-Market Stock Movers: BMY, ADBE, MSTR, AZN and More
Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%,...
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%,...
10
ColumnsTop upgrades and downgrades on 6/17: RBLX, AXP, CVS, GRAB and more
Upgrades
• $American Express(AXP.US$ : Baird Upgrades to Outperform from Neutral - PT $175
• $The AZEK(AZEK.US$ : BofA Securities Upgrades to Buy from Neutral
• $Capital One Financial(COF.US$ : Baird Upgrades to Outperform from Neutral - PT $145
• $Fifth Third Bancorp(FITB.US$ : Baird Upgrades to Outperform from Neutral - PT $44
• $M&T Bank(MTB.US$ : Baird Upgrades to Outperform from Neutral - PT $200 (from $175)
• $NextEra Energy Partners LP(NEP.US$ : RBC Cap...
• $American Express(AXP.US$ : Baird Upgrades to Outperform from Neutral - PT $175
• $The AZEK(AZEK.US$ : BofA Securities Upgrades to Buy from Neutral
• $Capital One Financial(COF.US$ : Baird Upgrades to Outperform from Neutral - PT $145
• $Fifth Third Bancorp(FITB.US$ : Baird Upgrades to Outperform from Neutral - PT $44
• $M&T Bank(MTB.US$ : Baird Upgrades to Outperform from Neutral - PT $200 (from $175)
• $NextEra Energy Partners LP(NEP.US$ : RBC Cap...
20
2
ColumnsToday's pre-market stock movers: CHWY, PATH, SNAP, HPE and more
Gainers:
• $Repare Therapeutics(RPTX.US$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy(CHWY.US$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath(PATH.US$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage(PSTG.US$ +10.6% (In reaction to earnings)
• $Credo Technology(CRDO.US$ +10.2% (In reaction ...
• $Repare Therapeutics(RPTX.US$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy(CHWY.US$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath(PATH.US$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage(PSTG.US$ +10.6% (In reaction to earnings)
• $Credo Technology(CRDO.US$ +10.2% (In reaction ...
19
$Centessa Pharmaceuticals(CNTA.US$ and $Schrodinger(SDGR.US$ will collaborate to discover therapies targeting the Orexin-2 receptor for sleep disorders.
The agreement will give Centessa subsidiary Orexia Therapeutics access to Schrodinger's computing platform. The platform allows for high performance computing in order to accurately predict the effectiveness of the target of interest.
The terms require Orexia to handle preclinical research activities, clinical development, and commercialization of potential candidates.
The agreement will give Centessa subsidiary Orexia Therapeutics access to Schrodinger's computing platform. The platform allows for high performance computing in order to accurately predict the effectiveness of the target of interest.
The terms require Orexia to handle preclinical research activities, clinical development, and commercialization of potential candidates.
4
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Jaguar8 : A big ouch
TrytosaveabitOP Jaguar8: Not as bad as I thought!
Jaguar8 TrytosaveabitOP: CYN was bad haha
TrytosaveabitOP Jaguar8: Yes it was! Hehehe
Jaguar8 TrytosaveabitOP: I’m sure a lot got caught off guard and end up bagholding. Scaling out is key
View more comments...